Skip to main content
Home > BC Innovations > Targets & Mechanisms

Chronological Index of : Targets & Mechanisms

 Current Issue
  • Table: BioCentury Product Profile

    Gut control Targets & Mechanisms BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product Akkermansia muciniphila or its protein Amuc_1100 Concept Pasteurization-stabilized form of a …

    Published on 1/12/2017
  • Table: Tapping the microbiome for metabolic disease

    Gut control Targets & Mechanisms Tapping the microbiome for metabolic disease Select companies and collaborations targeting the intestinal microbiome to treat obesity and other metabolic conditions. Source: BCIQ: …

    Published on 1/12/2017
  • Gut control

    Three new avenues for using the microbiome to treat obesity

    Separate studies highlight three connections between the microbiome and obesity - a protein, a bacterial species and a gut signature - with therapeutic and prognostic utility.

    Published on 1/12/2017
  • Opportunity Knocks

    BioCentury analyzes disease targets ripe for translation

    Analysis of BioCentury's BCIQ database shows industry is picking up only about one third of the hundreds of drug targets uncovered by academics every year.

    Published on 12/22/2016
  • Figure: Distillery disease breakdown

    Opportunity Knocks Targets & Mechanisms Distillery disease breakdown The fraction of Distillery items in each disease category published in BioCentury Innovations in 2012 (upper left) and 2016 (upper right), plus …

    Published on 12/22/2016
  • Figure: New targets arising

    Opportunity Knocks Targets & Mechanisms New targets arising Number of targets added to the BCIQ: BioCentury Online Intelligence database. * denotes data through Dec. 9. Source: BCIQ: BioCentury Online Intelligence

    Published on 12/22/2016
  • Figure: Targeting opportunity

    Opportunity Knocks Targets & Mechanisms Targeting opportunity Disease areas with largest number of targets that have commercial potential. Opportunity targets are those identified in BioCentury Innovations' …

    Published on 12/22/2016
  • Table: Top available targets

    Opportunity Knocks Targets & Mechanisms Top available targets Disease targets identified in BioCentury Innovations' Distillery that are not associated with any disclosed products in BioCentury's BCIQ database. …

    Published on 12/22/2016
  • Keeping the Gas off AXL

    Aravive has developed an AXL inhibitor with unprecedented affinity

    Aravive is using a different modality and mechanism of suppressing oncogenic AXL to outcompete the small molecule inhibitors already in development.

    Published on 12/15/2016
  • Figure: Metastases out of GAS6

    Keeping the Gas off AXL Targets & Mechanisms Metastases out of GAS6 In a paper in The Journal of Clinical Investigation, researchers from Stanford University and Aravive Biologics Inc. described an AXL decoy, MYD1-…

    Published on 12/15/2016
  • Table: BioCentury Product Profile

    Keeping the Gas off AXL Targets & Mechanisms BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product AXL decoy receptor Concept A protein based on the extracellular portion of AXL that …

    Published on 12/15/2016
  • Table: Putting the brakes on AXL

    Keeping the Gas off AXL Targets & Mechanisms Putting the brakes on AXL Select AXL receptor tyrosine kinase (AXL; UFO)-targeted therapeutics in clinical and preclinical development. At least three AXL inhibitors are…

    Published on 12/15/2016
  • Not a peripheral story

    Beyond peripheral autoimmunity in Type I diabetes

    By looking in pancreatic islets rather than blood, a UMass team has uncovered a trove of new antigens that drive Type I diabetes.

    Published on 12/1/2016
  • Figure: A lethal halo

    Not a peripheral story Targets & Mechanisms A lethal halo In a Nature Medicine study published in October, researchers from the University of Massachusetts Medical School profiled islet-infiltrating T cells from …

    Published on 12/1/2016
  • Figure: Stages of withdrawal

    Going against the gut Targets & Mechanisms Stages of withdrawal An NIH and Emory University team designed a five-stage protocol to test whether a mAb against integrin α4β7 would allow monkeys infected with SIV, the…

    Published on 11/3/2016
  • Going against the gut

    Why blocking T cell entry into the gut could get HIV patients off of ART

    An NIH group wants to boost immunity in HIV and wean patients off ART by blocking entry of T cells to the gut, where most of the virus lurks.

    Published on 11/3/2016
  • Cancer's Phoenix

    A safer IL-2-based immunotherapy without compromised efficacy

    Courier Therapeutics may have solved the longstanding problem of how to avoid the lethal side effects of IL-2 cancer immunotherapy without compromising efficacy.

    Published on 10/27/2016
  • Figure: Aim intermediate

    Cancer's Phoenix Targets & Mechanisms Aim intermediate To avoid dose-limiting toxicities associated with recombinant IL-2, researchers at Washington University in St. Louis have created a fusion protein that …

    Published on 10/27/2016
  • Figure: Check This Out

    Cancer's Phoenix Targets & Mechanisms Check This Out Therapeutic response rates for metastatic renal cell carcinoma (RCC) patients treated with high-dose IL-2 or anti-PD1 antibody therapies, broken down by complete…

    Published on 10/27/2016
  • Table: BioCentury Product Profile

    Cancer's Phoenix Targets & Mechanisms BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product A fusion protein comprising a mutant form of IL-2 with diminished CD25 binding, linked to the …

    Published on 10/27/2016
  • Table: Everything old is new again

    Cancer's Phoenix Targets & Mechanisms Everything old is new again IL-2-based therapeutics in clinical and preclinical development. At least seven products containing a form of IL-2 are in clinical development, and …

    Published on 10/27/2016
  • Figure: Both sides now

    T cell gas, tumor brake Targets & Mechanisms Both sides now Studies from two independent groups suggest targeting PGC-1α pathway functions could help treat cancer, either by enhancing the effects of T cell …

    Published on 10/27/2016
  • Figure: Both sides now

    T cell gas, tumor brake Targets & Mechanisms Both sides now Studies from two independent groups suggest targeting PGC-1α pathway functions could help treat cancer, either by enhancing the effects of T cell …

    Published on 10/27/2016
  • T cell gas, tumor brake

    Three studies pump the therapeutic potential of PGC-1α

    A trio of studies converge on a common pathway, headed by the PPAR co-activator PGC-1α, to improve T cell immunotherapies and suppress cancer metastasis.

    Published on 10/27/2016
  • Seeking cysteines

    Scripps team reveals Tecfidera's targets and how to drug them

    A Scripps team has identified PKCθ as a key target of Tecfidera and exposed a way to create isoform-selective inhibitors that extends far beyond PKC enzymes.

    Published on 10/6/2016

< Previous   1  2  3  4  5  Next >

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993